Lykos Therapeutics is shaking up its management team like a snow globe. Amy Emerson, who’s been steering the ship for nearly a decade, is stepping down but sticking around as a senior advisor and Board Observer—think Yoda in a business suit. Enter Michael Mullette, the former COO with a resume that reads like a pharmaceutical Hall of Fame, thanks to his stints at Sanofi and Moderna, where he helped roll out the COVID-19 vaccine. He’s now the interim CEO.
Meanwhile, Dr. David Hough, a psychiatrist who probably has more degrees than a thermometer, is the new Chief Medical Officer. He’s bringing his A-game from Johnson & Johnson to oversee the clinical development of midomafetamine (MDMA), which they’re testing for PTSD treatment—no, it’s not approved yet, but fingers crossed!
Lykos, which sounds like it could be a Greek god but is actually a Public Benefit Corporation (PBC), was founded by MAPS. They’re all about revolutionizing mental healthcare with investigational psychedelics, particularly MDMA-assisted therapy. This is not just for kicks; they’re leveraging decades of solid research to help people, communities, and society at large.
So, with a new captain at the helm and a top-notch medical officer in the mix, Lykos is all set to advance its pioneering mental healthcare treatments. If you want to know more, just hit up their website or follow them on social media.
In summary: New CEO, star-studded new CMO, same mission to transform mental healthcare with some good old-fashioned psychedelic research. Stay tuned for what’s next in this trippy journey!
Published Date: 2024-09-05